Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
Multimodal Ultrasound-Based Intelligent Classification and Treatment Response Prediction in the Dynamic Evolution of Lymphoma
This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.
Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.
The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.
研究概览
详细说明
This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.
Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.
The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.
Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.
The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Jie Yu, PhD
- 电话号码:01066937110
- 邮箱:jiemi301@163.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100853
- 招聘中
- Chinese PLA General Hospital
-
接触:
- Jie Yu, PhD
- 电话号码:+8601066937110
- 邮箱:jiemi301@163.com
-
首席研究员:
- Jie Yu, PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.
描述
Inclusion Criteria:
- Age 18 years or older.
- Histopathologically confirmed lymphoma.
- Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
- At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
- Expected survival of more than 3 months.
- No contraindication to the use of ultrasound contrast agents.
- Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written informed consent.
Exclusion Criteria:
- Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
- Known history of hypersensitivity to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
- Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
- Acute respiratory distress syndrome or severe respiratory insufficiency.
- Unstable angina or acute myocardial infarction within the previous 1 week.
- Pregnancy or breastfeeding.
- Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Newly Diagnosed Untreated Lymphoma Cohort
Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol. |
Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound
大体时间:After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays. |
After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density
大体时间:At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density
大体时间:At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival
大体时间:From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first. |
From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival
大体时间:From enrollment to death from any cause, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause. |
From enrollment to death from any cause, assessed through 24 months after enrollment.
|
|
Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists
大体时间:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Incidence of Study Ultrasound-Related Adverse Events
大体时间:From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented. |
From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
合作者和调查者
调查人员
- 首席研究员:Jie Yu, PhD、Chinese PLA General Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 2026-532
- U25C2048 (其他赠款/资助编号:National Natural Science Foundation of China)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.